A tolerance cure is the goal of retraining your immune system to permanently accept something it currently attacks, whether that’s a food protein, a transplanted organ, or your own tissue in an autoimmune disease. The word “cure” distinguishes it from treatments that only work while you keep taking them. In allergy medicine, where the term is most commonly used, a tolerance cure means you could stop treatment entirely and still eat the food or encounter the allergen without reacting, even months or years later.
Tolerance vs. Desensitization
The distinction between tolerance and desensitization is central to understanding what a tolerance cure actually promises. Desensitization means your body can handle an allergen right now, but only because you’ve been continuously exposed to it through treatment. If you stop eating the food or taking the therapy, the allergy can come back. True tolerance means the immune system has fundamentally changed its relationship with the allergen, so protection persists even after long gaps in exposure.
This difference plays out in real patients. In one study of children who completed cow’s milk immunotherapy, most were eating milk freely four years later. But one child stopped drinking milk for just one month after a viral illness and developed hives and asthma when he tried it again. In another study, children with egg allergy went through two full years of treatment. Four passed a food challenge at the end, but when researchers tested them again three to four months after stopping therapy, only two could still tolerate egg. One reacted to a dose as small as 24 milligrams. These cases illustrate why researchers are careful about calling any outcome a “cure.”
How the Immune System Shifts
Tolerance isn’t just the absence of a reaction. It involves measurable changes inside the immune system. The key shifts include a rise in protective antibodies (particularly one called IgG4) that block allergens from triggering the allergic cascade, a drop in the antibodies responsible for allergic reactions (IgE), and an increase in regulatory T cells, a type of immune cell whose job is to calm the rest of the immune system down.
An anti-inflammatory signaling molecule called IL-10 appears to orchestrate much of this process. During grass pollen immunotherapy, IL-10 levels rise within two to four weeks and precede the other immune changes. It suppresses the allergic arm of the immune response, encourages protective antibody production, and may even convert some attack-oriented immune cells into regulatory ones. When these changes are deep and durable enough, the result is lasting tolerance rather than temporary desensitization.
What Treatment Looks Like for Food Allergies
The most developed tolerance-oriented therapy is oral immunotherapy, or OIT. The concept is straightforward: you eat tiny, gradually increasing amounts of the food you’re allergic to until your immune system learns to tolerate it. In practice, this takes a long time and careful medical supervision.
Treatment typically starts with a buildup phase lasting months, where doses increase every one to two weeks in a clinic. Once you reach a maintenance dose, you eat that amount daily at home. For peanut allergy, a common maintenance target is 300 milligrams of peanut protein (roughly one peanut), though some protocols aim higher. Patients who want reliable protection against accidental exposures at that dose should expect to eat it daily for at least two years after reaching maintenance. For egg allergy, 55% of patients on a maintenance dose equivalent to about a third of an egg could tolerate a full egg after 10 months. After 22 months at the same dose, that number climbed to 75%.
The only FDA-approved oral immunotherapy product is Palforzia, indicated for peanut allergy in patients aged 4 to 17. It’s designed to reduce the severity of reactions after accidental peanut exposure, not to let someone eat peanut butter sandwiches freely. A separate medication, omalizumab, has also been approved to reduce the risk of allergic reactions to foods, though it works by a different mechanism.
How Researchers Define a “Cure”
Because true tolerance is hard to prove, allergy researchers use a carefully defined outcome called “sustained unresponsiveness.” This means a patient can pass a food challenge after completely avoiding the allergen for a set period, typically at least two weeks. The idea is simple: if you can stop eating the food and still not react when you encounter it again, your immune system has genuinely changed rather than just being temporarily suppressed.
In a landmark peanut study, 24 patients completed years of oral immunotherapy, then stopped treatment entirely. One month later, 12 of them (50%) passed a challenge involving 5,000 milligrams of peanut protein, roughly 16 peanuts, and then freely ate peanut butter without symptoms. The other half had lost their protection. By intent-to-treat analysis, which counts everyone who originally enrolled including dropouts, the success rate was 31%. These numbers represent the current reality of tolerance cures: achievable for some, but far from guaranteed.
Safety During Treatment
Oral immunotherapy carries real risks because it involves deliberately feeding someone a food that causes allergic reactions. In a large Canadian study of 270 preschool-age children undergoing peanut OIT, about 4% of patients experienced a systemic reaction requiring epinephrine at some point during treatment. On a per-dose basis, the risk was much lower: roughly 0.03% of all doses, or about 1 in 3,400. Most serious reactions happened during supervised clinic visits rather than at home. For context, these rates are actually lower than those seen with traditional allergy shots for environmental allergens, where one study found 7.4% of patients needed epinephrine.
Beyond Food Allergies
The concept of a tolerance cure extends well beyond food. In organ transplantation, the goal is to get the recipient’s immune system to accept the donor organ without lifelong immunosuppressive drugs. Several experimental protocols attempt this by creating a state called chimerism, where the recipient’s bone marrow contains some donor cells, effectively teaching the immune system to see the transplanted organ as “self.” Other approaches include transplanting thymus tissue to re-educate developing immune cells, or infusing regulatory T cells to suppress rejection.
In autoimmune diseases like type 1 diabetes, rheumatoid arthritis, and multiple sclerosis, the immune system attacks the body’s own tissue. Tolerance therapies here aim to call off that attack without suppressing the entire immune system. One approach uses tolerogenic dendritic cells, immune cells engineered to exist in a semi-activated state that promotes tolerance rather than inflammation. These cells secrete anti-inflammatory signals and teach other immune cells to stand down. Clinical trials are testing this approach in multiple sclerosis, rheumatoid arthritis, and type 1 diabetes.
Another strategy uses engineered CAR T cells, but instead of targeting cancer, they’re designed to eliminate the specific immune cells driving the autoimmune attack. In mouse models of multiple sclerosis, this approach has reversed disease by wiping out the T cells that attack the protective coating around nerves. A more dramatic version targets all B cells to essentially reset the immune system, removing the disease-causing clones and allowing tolerance to re-establish itself as the immune system rebuilds. Clinical trials are now testing this in several autoimmune conditions.